Suppr超能文献

KRAS 剪接变异体的差异功能。

Differential functions of the KRAS splice variants.

机构信息

Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, U.S.A.

出版信息

Biochem Soc Trans. 2023 Jun 28;51(3):1191-1199. doi: 10.1042/BST20221347.

Abstract

RAS proteins are small GTPases that transduce signals from membrane receptors to signaling pathways that regulate growth and differentiation. Four RAS proteins are encoded by three genes - HRAS, KRAS, NRAS. Among them, KRAS is mutated in human cancer more frequently than any other oncogene. The KRAS pre-mRNA is alternatively spliced to generate two transcripts, KRAS4A and KRAS4B, that encode distinct proto-oncoproteins that differ almost exclusively in their C-terminal hypervariable regions (HVRs) that controls subcellular trafficking and membrane association. The KRAS4A isoform arose 475 million years ago in jawed vertebrates and has persisted in all vertebrates ever since, strongly suggesting non-overlapping functions of the splice variants. Because KRAS4B is expressed at higher levels in most tissues, it has been considered the principal KRAS isoform. However, emerging evidence for KRAS4A expression in tumors and splice variant-specific interactions and functions have sparked interest in this gene product. Among these findings, the KRAS4A-specific regulation of hexokinase I is a stark example. The aim of this mini-review is to provide an overview of the origin and differential functions of the two splice variants of KRAS.

摘要

RAS 蛋白是一种小的 GTP 酶,可将信号从膜受体转导至调节生长和分化的信号通路。三种基因 HRAS、KRAS、NRAS 编码四种 RAS 蛋白。其中,KRAS 的突变在人类癌症中比任何其他癌基因都更频繁。KRAS 前体 mRNA 选择性剪接产生两种转录本,KRAS4A 和 KRAS4B,它们编码不同的原癌蛋白,几乎只在其 C 末端的高变区(HVR)中不同,该区域控制细胞内运输和膜结合。KRAS4A 异构体在 4.75 亿年前出现在有颌脊椎动物中,此后一直存在于所有脊椎动物中,强烈表明剪接变体具有非重叠的功能。由于 KRAS4B 在大多数组织中的表达水平更高,因此它被认为是主要的 KRAS 异构体。然而,越来越多的证据表明 KRAS4A 在肿瘤中的表达以及剪接变体特异性相互作用和功能,这引起了人们对该基因产物的兴趣。在这些发现中,KRAS4A 对己糖激酶 I 的特异性调节是一个明显的例子。本综述的目的是概述 KRAS 两种剪接变体的起源和差异功能。

相似文献

1
Differential functions of the KRAS splice variants.
Biochem Soc Trans. 2023 Jun 28;51(3):1191-1199. doi: 10.1042/BST20221347.
2
The role of KRAS splice variants in cancer biology.
Front Cell Dev Biol. 2022 Nov 1;10:1033348. doi: 10.3389/fcell.2022.1033348. eCollection 2022.
3
Origin and Evolution of RAS Membrane Targeting.
Oncogene. 2023 May;42(21):1741-1750. doi: 10.1038/s41388-023-02672-z. Epub 2023 Apr 8.
4
Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Sci Adv. 2024 Feb 16;10(7):eadj4137. doi: 10.1126/sciadv.adj4137. Epub 2024 Feb 14.
5
Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Oncogene. 2023 Apr;42(15):1224-1232. doi: 10.1038/s41388-023-02638-1. Epub 2023 Mar 2.
7
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30). doi: 10.1073/pnas.2023112118.
8
Origin and evolution of RAS oncoprotein membrane targeting.
Res Sq. 2023 Jan 20:rs.3.rs-2485219. doi: 10.21203/rs.3.rs-2485219/v1.
9
KRAS4A directly regulates hexokinase 1.
Nature. 2019 Dec;576(7787):482-486. doi: 10.1038/s41586-019-1832-9. Epub 2019 Dec 11.
10
Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.
J Biol Chem. 2023 Jan;299(1):102768. doi: 10.1016/j.jbc.2022.102768. Epub 2022 Dec 5.

引用本文的文献

1
Targeting KRAS in colorectal cancer (Review).
Mol Clin Oncol. 2025 Jul 3;23(3):78. doi: 10.3892/mco.2025.2873. eCollection 2025 Sep.
2
"Undruggable KRAS": druggable after all.
Genes Dev. 2025 Jan 7;39(1-2):132-162. doi: 10.1101/gad.352081.124.
3
Aberrant pre-mRNA processing in cancer.
J Exp Med. 2024 Nov 4;221(11). doi: 10.1084/jem.20230891. Epub 2024 Sep 24.
4
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z.

本文引用的文献

1
Origin and Evolution of RAS Membrane Targeting.
Oncogene. 2023 May;42(21):1741-1750. doi: 10.1038/s41388-023-02672-z. Epub 2023 Apr 8.
2
Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Oncogene. 2023 Apr;42(15):1224-1232. doi: 10.1038/s41388-023-02638-1. Epub 2023 Mar 2.
3
The role of KRAS splice variants in cancer biology.
Front Cell Dev Biol. 2022 Nov 1;10:1033348. doi: 10.3389/fcell.2022.1033348. eCollection 2022.
4
The current state of the art and future trends in RAS-targeted cancer therapies.
Nat Rev Clin Oncol. 2022 Oct;19(10):637-655. doi: 10.1038/s41571-022-00671-9. Epub 2022 Aug 26.
5
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.
Proc Natl Acad Sci U S A. 2021 Aug 17;118(33). doi: 10.1073/pnas.2103261118.
6
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30). doi: 10.1073/pnas.2023112118.
7
Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells.
Nat Commun. 2021 Jul 13;12(1):4288. doi: 10.1038/s41467-021-24498-7.
8
The Ins and Outs of RAS Effector Complexes.
Biomolecules. 2021 Feb 7;11(2):236. doi: 10.3390/biom11020236.
9
The Frequency of Ras Mutations in Cancer.
Cancer Res. 2020 Jul 15;80(14):2969-2974. doi: 10.1158/0008-5472.CAN-19-3682. Epub 2020 Mar 24.
10
KRAS4A directly regulates hexokinase 1.
Nature. 2019 Dec;576(7787):482-486. doi: 10.1038/s41586-019-1832-9. Epub 2019 Dec 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验